New Inhalation Formulations for Improved Delivery of Antimicrobials
| Reference number | |
| Coordinator | RISE Research Institutes of Sweden AB |
| Funding from Vinnova | SEK 4 137 500 |
| Project duration | November 2022 - December 2025 |
| Status | Completed |
| Venture | European partnership for antimicrobial resistance |
| Call | JPI AMR Joint Transnational Call 2022: Disrupting drug Resistance Using Innovative Design. |
Important results from the project
The project achieved its goals by developing and testing five inhalation formulations of apramycin. Several showed promising results, including improved efficacy and favorable aerosol properties. One formulation demonstrated enhanced antimicrobial effect against A. baumannii in vitro and in vivo (patent filed). The project generated extensive preclinical data—PK studies, bioanalysis and toxicology—supporting further progression toward clinical development.
Expected long term effects
The project is expected to advance the development of new inhaled antibiotics for difficult‑to‑treat lung infections. The results support further preclinical progression toward clinical studies and highlight the importance of formulation, providing valuable insights for other antimicrobials. Long term, this may improve treatment outcomes, reduce resistance, and strengthen future innovation in inhalation therapy.
Approach and implementation
The project was carried out as planned, developing, characterizing, and evaluating five formulations. Despite organizational changes and bioanalysis adjustments, the timeline was largely maintained. Collaboration worked effectively, and required adaptations were successfully managed through active coordination within the consortium.